BCM
SMMT icon

Bayesian Capital Management’s Summit Therapeutics SMMT Stock Holding History

Bayesian Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
+17,200
New +$305K 0.16% 175
2025
Q1 		– Sell
-67,039
Closed -$1.2M – 933
2024
Q4 		$1.2M Buy
+67,039
New +$1.3M 0.15% 204
2024
Q3 		– Sell
-16,499
Closed -$129K – 1013
2024
Q2 		$129K Buy
+16,499
New +$89.1K 0.01% 643

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bayesian Capital Management's SMMT Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 17,200 shares worth $251K. The stake represents 0.16% of the portfolio and ranks #175 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in SMMT as recently as Q4 2024.

Bayesian Capital Management first reported a position in SMMT in Q2 2024 and has held it in 3 quarters since. The position peaked at $1.2M in Q4 2024. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Bayesian Capital Management held 17,200 shares of Summit Therapeutics worth $251K as of Q2 2026.
  • Summit Therapeutics was a new Bayesian Capital Management position in Q2 2026.
  • Summit Therapeutics made up 0.16% of Bayesian Capital Management's portfolio in Q2 2026, its #175 holding.
  • Bayesian Capital Management first reported a position in Summit Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Bayesian Capital Management's Summit Therapeutics position peaked at $1.2M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.